ArticleCureus2026
Prescribing Trends of Antihypertensive Medications: An Observational Study in a Tertiary Care Hospital in India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesHypertension is a major contributor to cardiovascular morbidity and mortality and represents a significant public health burden in India and blood pressure control rates remain low, contributing substantially to cardiovascular disease (CVD) risk. Appropriate pharmacological management at the time of diagnosis is essential for effective blood pressure control and prevention of complications. This study aimed to assess the demographic profile, comorbidities, and antihypertensive prescribing patterns among newly diagnosed hypertensive patients in a tertiary care hospital. The distribution of patients was classified according to the American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines (2017), with consideration of subsequent updates, including the most recent 2025 recommendations, and prescribing trends based on World Health Organization (WHO) prescribing indicators were also analyzed.
methodsThis cross-sectional observational study included 250 adult patients newly diagnosed with hypertension. Data regarding demographic characteristics, lifestyle factors, body mass index (BMI), associated comorbidities, and prescribed antihypertensive medications were collected. Patients were categorized by age, BMI, and hypertension staging as per the latest ACC/AHA guidelines. Drug utilization patterns were evaluated using WHO prescribing indicators.
resultsThe mean age of participants was 54.9 ± 13.0 years, and the mean BMI was 27.8 ± 5.9 kg/m². Individuals aged over 50 years constituted 60% of the study population, and approximately 70% were overweight or obese. Most patients were married, literate, and belonged to socio-economic class III, representing individuals with moderate educational attainment, semi-skilled or clerical occupations, and a middle-range household income relative to the urban population. Diabetes mellitus was the most common comorbidity (47.6%), followed by CVD (22.8%). Combination therapy was prescribed more frequently than monotherapy, with an average of 1.56 antihypertensive drugs per patient. Angiotensin receptor blockers (ARBs) were the most commonly prescribed agents. WHO indicators demonstrated rational prescribing, with high use of generic medicines and essential drugs.
conclusionThe study highlights a high burden of hypertension among older, overweight, and diabetic individuals. Prescribing practices predominantly favored ARBs and reflected rational, guideline-consistent management of hypertension in a tertiary care setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.